bluuebunny/crossref_metadata_2025_split huggingface dataset:
0‐D and 1‐D Perovskite‐like Hybrid Bismuth(III) Iodides
Authors: Saraswat Aditi , Vishnoi Pratap 
Published: March 2024

AbstractLow‐dimensional hybrid bismuth halide perovskites have recently emerged as a class of non‐toxic alternative to lead perovskites with promising optoelectronic properties. Here, we report three hybrid bismuth(III)‐iodides: 0‐D (H2DAC)2Bi2I10 ⋅ 6H2O (H2DAC_Bi_I), 0‐D (H2DAF)4Bi2I10 ⋅ 2I3 ⋅ 2I ⋅ 6H2O (H2DAF_Bi_I), and 1‐D (H2DAP)BiI5 (H2DAP_Bi_I) (where H2DAC=trans‐1,4‐diammoniumcyclohexane; H2DAF=2,7‐diammoniumfluorene and H2DAP=1,5‐diammoniumpentane). Their synthesis, single‐crystal X‐ray structures, and photophysical properties are reported. The first two compounds comprise edge‐sharing [Bi2I10]4− dimers, while the last compound has cis‐corner‐sharing 1‐D chains of [BiI6]3− octahedra. Intercalation of triiodide (I3−) and iodide (I−) ions enhance electronic coupling between the [Bi2I10]4− of H2DAF_Bi_I, leading to enhanced optical absorption, compared to H2DAC_Bi_I which lacks such intercalants. Furthermore, calorimetric and variable temperature X‐ray diffraction measurements suggest a centrosymmetric to non‐centrosymmetric phase transition (monoclinic P212121↔orthorhombic Pnma) of H2DAP_Bi_I at 448 K (in heating step) and at 443 K (in cooling step).
Dynamic functional connectivity in the right temporoparietal junction captures variations in male autistic trait expression
Authors: Bravo Balsa Laura , Abu‐Akel Ahmad , Mevorach Carmel 
Published: March 2024

AbstractAutistic individuals can experience difficulties with attention reorienting and Theory of Mind (ToM), which are closely associated with anterior and posterior subdivisions of the right temporoparietal junction. While the link between these processes remains unclear, it is likely subserved by a dynamic crosstalk between these two subdivisions. We, therefore, examined the dynamic functional connectivity (dFC) between the anterior and posterior temporoparietal junction, as a biological marker of attention and ToM, to test its contribution to the manifestation of autistic trait expression in Autism Spectrum Condition (ASC). Two studies were conducted, exploratory (14 ASC, 15 TD) and replication (29 ASC, 29 TD), using resting‐state fMRI data and the Social Responsiveness Scale (SRS) from the Autism Brain Imaging Data Exchange repository. Dynamic Independent Component Analysis was performed in both datasets using the CONN toolbox. An additional sliding‐window analysis was performed in the replication study to explore different connectivity states (from highly negatively to highly positively correlated). Dynamic FC was reduced in ASC compared to TD adults in both the exploratory and replication datasets and was associated with increased SRS scores (especially in ASC). Regression analyses revealed that decreased SRS autistic expression was predicted by engagement of highly negatively correlated states, while engagement of highly positively correlated states predicted increased expression. These findings provided consistent evidence that the difficulties observed in ASC are associated with altered patterns of dFC between brain regions subserving attention reorienting and ToM processes and may serve as a biomarker of autistic trait expression.
Update on the impact of voluntary folic acid fortification of corn masa flour on red blood cell folate concentrations—National Health and Nutrition Examination Survey, 2011–March 2020
Authors: Wang Arick , Fothergill Amy , Yeung Lorraine F. , Crider Krista S. , Williams Jennifer L. 
Published: March 2024

AbstractBackgroundFolic acid is a micronutrient that is effective at preventing neural tube defects (NTDs). In 2016, the FDA authorized the voluntary fortification of corn masa flour (CMF) with folic acid to reduce disparities in NTDs among infants of women who do not regularly consume other fortified cereal grains, in particular Hispanic women of reproductive age (WRA).MethodsWe analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2011 to March 2020 assessing the impact of voluntary fortification of CMF on the folate status of Hispanic WRA. We analyzed folic acid usual intake and red blood cell (RBC) folate concentrations among non‐pregnant, non‐lactating Hispanic WRA, comparing pre‐fortification (2011–2016) to post‐fortification (2017–March 2020) data. RBC folate concentrations were used to create model‐based estimation of NTD rates.ResultsThe proportion of Hispanic WRA with folic acid usual intakes <400 μg/d did not change (2011–2016: 86.1% [95% Confidence Interval, CI: 83.7–88.5]; 2017–March 2020: 87.8% [95% CI: 84.8–90.7]; p = .38) nor did the proportion of Hispanic WRA with RBC folate below optimal concentrations (<748 nmol/L, 2011–2016: 16.0% [95% CI: 13.7–18.2]; 2017–March 2020: 18.1% [95% CI: 12.1–24.0]; p = 0.49). Model‐based estimates of NTD rates suggest further improvements in the folate status of Hispanic WRA might prevent an additional 157 (95% Uncertainty Interval: 0, 288) NTDs/year.ConclusionsVoluntary fortification of CMF with folic acid has yet to have a significant impact on the folate status of WRA. Continued monitoring and further research into factors such as fortified product availability, community knowledge, and awareness of folic acid benefits would inform and improve future public health interventions.
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study
Authors: Li Doudou , Jin Yizi , Lin Mingxi , Zeng Cheng , Guo Qing , Liu Yanfei , Zhang Jian 
Published: March 2024

AbstractBackgroundChidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)‐positive and HER2‐negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological factors that predict the efficacy of chidamide in real‐world scenarios.MethodsConsecutive MBC patients treated with chidamide from January 2020 to August 2021 across 11 institutions were enrolled in this multicenter, retrospective study. Eligible patients were pre‐ and postmenopausal women who had clinically or histologically confirmed ER‐positive, HER2‐negative MBC, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients with multiple primary malignancies or missing baseline characteristics were excluded. Patients received 30 mg chidamide orally twice a week, combined with aromatase inhibitors (AIs) or non‐AIs. Efficacy analyses included progression‐free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR). Univariate and multivariate Cox regression analyses were performed to identify the potential efficacy predictors.ResultsA total of 157 patients were finally included for analysis. The median number of lines prior to chidamide was four. In the whole cohort, the median PFS was 4.2 months (95% confidence interval [CI] 3.8–4.5). The ORR was 7.5% and the CBR was 31.3%. The efficacy of chidamide was consistent in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations. Multivariate analysis indicated that patients who had liver metastases (adjusted HR = 1.66, 95% CI 1.14–2.43, adjusted p = 0.008) or ≥3 prior lines of treatment (adjusted HR = 1.80, 95% CI 1.17–2.77, adjusted p = 0.008) had significantly worse PFS. The most common AEs with chidamide were thrombocytopenia, leucopenia, neutropenia, and anemia.ConclusionThis study provided real‐world data for the use of chidamide in patients with HoR‐positive and HER2‐negative MBC. Our data endorsed the use of chidamide in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations.
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial
Authors: Murakami Eriko , Akamatsu Hiroaki , Teraoka Shunsuke , Takakura Toshiaki , Takase Eri , Tanaka Masanori , Kaki Takahiro , Harutani Yuhei , Furuta Katsuyuki , Sugimoto Takeya , Shibaki Ryota , Fujimoto Daichi , Hayata Atsushi , Ozawa Yuichi , Nakanishi Masanori , Koh Yasuhiro , Shimokawa Toshio , Yamamoto Nobuyuki 
Published: March 2024

AbstractBackgroundMannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires clarification.MethodsThis is a prospective, single‐centered, open‐label, noninferiority phase II study. Patients with thoracic malignancies who planned to receive CDDP‐based chemotherapy were randomly assigned to receive either mannitol (arm A) or furosemide (arm B). The primary end point was set as the proportion of patients who experienced any grade of “creatinine (Cr) increased” based on the upper limit of the normal range (ULN) during the first cycle as assessed by Common Terminology Criteria for Adverse Events Version 4.0. Secondary end points were Cr increased based on the baseline value during the first cycle, Cr increased after the completion of CDDP, and the proportion of patients with phlebitis.ResultsBetween April 2018 and March 2022, 115 patients were enrolled and 106 were analyzed. Any grade of Cr increased based on the ULN during the first cycle was 17.3% (arm A) and 24.1% (arm B), respectively (p = 0.34). Therefore, the primary end point was not met. After completion of chemotherapy, any grade of Cr increased was observed in 23.1% (arm A) and 31.5% (arm B), respectively. However, the actual serum Cr level and Cr clearance during the courses were not different between the arms. Phlebitis occurred more frequently in arm A (28.8%) than arm B (16.7%).ConclusionsMannitol should remain the standard diuresis in CDDP‐based chemotherapy assessed by conventional CTCAE grading, but furosemide can be room for consideration when assessed by actual serum Cr level and Cr clearance.
Radiation enteropathy‐related depression: A neglectable course of disease by gut bacterial dysbiosis
Authors: Liu Xinliang , Li Ying , Gu Meichen , Xu Tiankai , Wang Chuanlei , Chang Pengyu 
Published: March 2024

AbstractRadiation enteropathy (RE) is common in patients treated with radiotherapy for pelvic–abdominal cancers. Accumulating data indicate that gut commensal bacteria determine intestinal radiosensitivity. Radiotherapy can result in gut bacterial dysbiosis. Gut bacterial dysbiosis contributes to the pathogenesis of RE. Mild to moderate depressive symptoms can be observed in patients with RE in clinical settings; however, the rate of these symptoms has not been reported. Studies have demonstrated that gut bacterial dysbiosis induces depression. In the state of comorbidity, RE and depression may be understood as local and abscopal manifestations of gut bacterial disorders. The ability of comorbid depression to worsen inflammatory bowel disease (IBD) has long been demonstrated and is associated with dysfunction of cholinergic neural anti‐inflammatory pathways. There is a lack of direct evidence for RE comorbid with depression. It is widely accepted that RE shares similar pathophysiologic mechanisms with IBD. Therefore, we may be able to draw on the findings of the relationship between IBD and depression. This review will explore the relationship between gut bacteria, RE, and depression in light of the available evidence and indicate a method for investigating the mechanisms of RE combined with depression. We will also describe new developments in the treatment of RE with probiotics, prebiotics, and fecal microbial transplantation.
Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real‐world study
Authors: Ottaiano Alessandro , Santorsola Mariachiara , Diana Anna , Belli Andrea , Lentini Graziano Maria Luisa , Orefice Jessica , Patrone Renato , Di Mauro Annabella , Scognamiglio Giosuè , Tatangelo Fabiana , De Bellis Mario , Piccirillo Mauro , Fiore Francesco , Stilo Salvatore , Tarotto Luca , Correra Marco , Di Lorenzo Sara , Capuozzo Maurizio , Avallone Antonio , Silvestro Lucrezia , Bianco Antonella , Granata Vincenza , Federico Piera , Montesarchio Vincenzo , Daniele Bruno , Izzo Francesco , Nasti Guglielmo 
Published: March 2024

AbstractBackground and AimsCholangiocarcinoma (CCA), a rare and aggressive hepatobiliary malignancy, presents significant clinical management challenges. Despite rising incidence and evolving treatment options, prognosis remains poor, motivating the exploration of real‐world data for enhanced understanding and patient care.MethodsThis multicenter study analyzed data from 120 metastatic CCA patients at three institutions from 2016 to 2023. Kaplan–Meier curves assessed overall survival (OS), while univariate and multivariate analyses evaluated links between clinical variables (age, gender, tumor site, metastatic burden, ECOG performance status, response to first‐line chemotherapy) and OS. Genetic profiling was conducted selectively.ResultsEnrolled patients had a median age of 68.5 years, with intrahepatic tumors predominant in 79 cases (65.8%). Among 85 patients treated with first‐line chemotherapy, cisplatin and gemcitabine (41.1%) was the most common regimen. Notably, one‐third received no systemic treatment. After a median 14‐month follow‐up, 81 CCA‐related deaths occurred, with a median survival of 13.1 months. Two clinical variables independently predicted survival: response to first‐line chemotherapy (disease control vs. no disease control; HR: 0.27; 95% CI: 0.14–0.50; p < 0.0001) and metastatic involvement (>1 site vs. 1 site; HR: 1.99; 95% CI: 1.04–3.80; p = 0.0366). The three most common genetic alterations involved the ARID1A, tp53, and CDKN2A genes.ConclusionsAdvanced CCA displays aggressive clinical behavior, emphasizing the need for treatments beyond chemotherapy. Genetic diversity supports potential personalized therapies. Collaborative research and deeper CCA biology understanding are crucial to enhance patient outcomes in this challenging malignancy.
Pivotal role of myeloid‐derived suppressor cells in infection‐related tumor growth
Authors: Ito Nozomi , Tsujimoto Hironori , Miyazaki Hiromi , Takahata Risa , Ueno Hideki 
Published: March 2024

AbstractBackgroundIn this study, we investigated infection‐related tumor growth, focusing on myeloid‐derived suppressor cells (MDSCs) in clinical and experimental settings.Patients and MethodsIn the clinical study, a total 109 patients who underwent gastrectomy or esophagectomy were included. Blood samples were collected from a preoperative time point through 3 months after surgery, and MDSCs were analyzed using flow cytometry. In animal experiments, peritonitis model mice were created by CLP method. We investigated the number of splenic MDSCs in these mice using flow cytometry. Malignant melanoma cells (B16F10) were inoculated on the back of the mice, and tumor growth was monitored. We compared the level of MDSC infiltration around the tumor and the migration ability between CLP and sham‐operated mice‐derived MDSCs. Finally, we focused on PD‐L1+MDSCs to examine the effectiveness of anti‐PD‐L1 antibodies on tumor growth in CLP mice.ResultsIn patients with postoperative infectious complication, MDSC number was found to remain elevated 3 months after surgery, when the inflammatory responses were normalized. CLP mice showed increased numbers of MDSCs, and following inoculation with B16F10 cells, this higher number of MDSCs was associated with significant tumor growth. CLP‐mice‐derived MDSCs had higher levels of accumulation around the tumor and had more enhanced migration ability. Finally, CLP mice had increased numbers of PD‐L1+MDSCs and showed more effective inhibition of tumor growth by anti‐PD‐L1 antibodies compared to sham‐operated mice.ConclusionLong‐lasting enhanced MDSCs associated with infection may contribute to infection‐related tumor progression.
POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
Authors: Liu Ge , Jin Kaifeng , Liu Zhaopei , Su Xiaohe , Xu Ziyue , Li Bingyu , Xu Jingtong , Chang Yuan , Wang Yiwei , Zhu Yu , Xu Le , Xu Jiejie , Wang Zewei , Liu Hailong , Zhang Weijuan 
Published: March 2024

AbstractBackgroundThough programmed cell death‐ligand 1 (PD‐L1) has been used in predicting the efficacy of immune checkpoint blockade (ICB), it is insufficient as a single biomarker. As a key effector of an intrinsically mutagenic microhomology‐mediated end joining (MMEJ) pathway, DNA polymerase theta (POLQ) was overexpressed in various malignancies, whose expression might have an influence on genomic stability, therefore altering the sensitivity to chemotherapy and immunotherapy.MethodsA total of 1304 patients with muscle‐invasive bladder cancer (MIBC) from six independent cohorts were included in this study. The Zhongshan Hospital (ZSHS) cohort (n = 134), The Cancer Genome Atlas (TCGA) cohort (n = 391), and the Neo‐cohort (n = 148) were included for the investigation of chemotherapeutic response. The IMvigor210 cohort (n = 234) and the UNC‐108 cohort (n = 89) were used for the assessment of immunotherapeutic response. In addition, the relationship between POLQ and the immune microenvironment was assessed, and GSE32894 (n = 308) was used only for the evaluation of the immune microenvironment.ResultsWe identified POLQhigh PD‐L1high patients could benefit more from immunotherapy and platinum‐based chemotherapy. Further analysis revealed that high POLQ expression was linked to chromosome instability and higher tumor mutational burden (TMB), which might elicit the production of neoantigens. Further, high POLQ expression was associated with an active tumor immune microenvironment with abundant infiltration of immune effector cells and molecules.ConclusionsThe study demonstrated that high POLQ expression was correlated with chromosome instability and antitumor immune microenvironment in MIBC, and the combination of POLQ and PD‐L1 could be used as a superior companion biomarker for predicting the efficacy of immunotherapy.
Phenome‐wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers
Authors: Mulugeta Anwar , Lumsden Amanda L. , Madakkatel Iqbal , Stacey David , Lee S. Hong , Mäenpää Johanna , Oehler Martin K. , Hyppönen Elina 
Published: March 2024

AbstractBackgroundOvarian cancer (OC) is commonly diagnosed among older women who have comorbidities. This hypothesis‐free phenome‐wide association study (PheWAS) aimed to identify comorbidities associated with OC, as well as traits that share a genetic architecture with OC.MethodsWe used data from 181,203 white British female UK Biobank participants and analysed OC and OC subtype‐specific genetic risk scores (OC‐GRS) for an association with 889 diseases and 43 other traits. We conducted PheWAS and colocalization analyses for individual variants to identify evidence for shared genetic architecture.ResultsThe OC‐GRS was associated with 10 diseases, and the clear cell OC‐GRS was associated with five diseases at the FDR threshold (p = 5.6 × 10−4). Mendelian randomizaiton analysis (MR) provided robust evidence for the association of OC with higher risk of “secondary malignant neoplasm of digestive systems” (OR 1.64, 95% CI 1.33, 2.02), “ascites” (1.48, 95% CI 1.17, 1.86), “chronic airway obstruction” (1.17, 95% CI 1.07, 1.29), and “abnormal findings on examination of the lung” (1.51, 95% CI 1.22, 1.87). Analyses of lung spirometry measures provided further support for compromised respiratory function. PheWAS on individual OC variants identified five genetic variants associated with other diseases, and seven variants associated with biomarkers (all, p ≤ 4.5 × 10−8). Colocalization analysis identified rs4449583 (from TERT locus) as the shared causal variant for OC and seborrheic keratosis.ConclusionsOC is associated with digestive and respiratory comorbidities. Several variants affecting OC risk were associated with other diseases and biomarkers, with this study identifying a novel genetic locus shared between OC and skin conditions.
Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
Authors: Jiang Yi Li , Mu Juan , Cui Rui , Li Xin , Wang Jia , Li Qing , Li Jingyi , Mou Nan , Deng Qi 
Published: March 2024

AbstractIntroductionAlthough anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient.MethodsWe summarized the efficacy and side effects of anti‐CD19 CAR T‐cell therapy in 12 patients with R/R GI lymphoma. Based on literature, the R/R GI lymphoma patients were divided into subgroups with different characteristics: Bulky/No bulky disease, Gastric/Gastrointestinal involvement, Gastrointestinal/Combined extra‐gastrointestinal lesions, Ulcer/Lumps or nodules type, With/without gastrointestinal bleeding.ResultsThe objective response rate (ORR) was 66.67% in these 12 patients. The ORR was 83.33% in no bulky disease group, 80.00% in gastric involvement group, 100.00% in ulcer type group, and 80.00% in no gastrointestinal bleeding group. The CR rate was 33.33% in these 12 patients. The CR was 50.0% in no bulky disease group, 60.00% in gastric involvement group, and 80.00% in ulcer type group. The PFS and OS rate of the 12 patients at 6 months after infusion were 54.55% and 58.33%, respectively. The overall survival (OS) at 6 months was higher in no bulky disease group. There was no difference of the OS or the progression free survival (PFS) at 6 months between the other groups. The mean peak of CAR‐T cells and Cytokine Release Syndrome (CRS) grade were higher in gastrointestinal lesions group. The mean peak of IFN‐γ and CRS grade were higher in gastrointestinal bleeding group. Four out of six patients in group of gastrointestinal lesions group were patient with high tumor burden. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding.ConclusionsThe ORR and CR of high tumor load, gastrointestinal involvement, lumps or nodules type and gastrointestinal bleeding group were lower. The CRS grade was higher in gastrointestinal lesions group and in gastrointestinal bleeding group. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding.
An automatic parathyroid recognition and segmentation model based on deep learning of near‐infrared autofluorescence imaging
Authors: Yu Fan , Sang Tian , Kang Jie , Deng Xianzhao , Guo Bomin , Yang Hangzhou , Chen Xiaoyi , Fan Youben , Ding Xuehai , Wu Bo 
Published: March 2024

AbstractIntroductionNear‐infrared autofluorescence imaging (NIFI) can be used to identify parathyroid gland (PG) during surgery. The purpose of the study is to establish a new model, help surgeons better identify, and protect PGs.MethodsFive hundred and twenty three NIFI images were selected. The PGs were recorded by NIFI and marked with artificial intelligence (AI) model. The recognition rate for PGs was calculated. Analyze the differences between surgeons of different years of experience and AI recognition, and evaluate the diagnostic and therapeutic efficacy of AI model.ResultsOur model achieved 83.5% precision and 57.8% recall in the internal validation set. The visual recognition rate of AI model was 85.2% and 82.4% on internal and external sets. The PG recognition rate of AI model is higher than that of junior surgeons (p < 0.05).ConclusionsThis AI model will help surgeons identify PGs, and develop their learning ability and self‐confidence.